the present study, we investigated the developmental changes of: (1) plasma and erythrocyte tetrahydrobiopterin (BH4); (2) erythrocyte GTP cyclohydrolase (the rate-limiting enzyme of BH4 biosynthesis); (3) the permeability of erythrocyte membrane to BH4; and (4) plasma phenylalanine, both in healthy human subjects and Wistar rats. In vitro experiments demonstrated passive transport of BH4 into erythrocytes. In humans, BH4 levels as well as the other parameters were fairly consistent across all age groups. In contrast, Wistar rats showed significant developmental changes in erythrocyte BH4, which were not simply correlated to either GTP cyclohydrolase, permeability to BH4, or plasma phenylalanine levels. This may suggest the existence of other factors regulating the homeostasis of BH4, such as BH4-binding capacity in plasma and/or erythrocytes. These species/age differences in erythrocyte characteristics may influence the pharmacological behavior and clinical efficacy of BH4 in humans and experimental animals. Key Words tetrahydrobiopterin, erythrocyte, GTP cyclohydrolase, permeability, phenylalanine, developmental change, human subject, Wistar rat Human mature erythrocytes (RBCs) and plasma have been demonstrated to contain comparable amounts of tetrahydrobiopterin (BH4) (1,2), in spite of a lack of BH4-requiring systems, i.e. the hydroxylation of phenylalanine (3), the biosyntheses of catecholamines (4), serotonin (5) and nitric oxide (6, 7) in RBCs. Because of the variety of physiological roles of BH4, its potential as a therapeutic agent appears to be expanding for many clinical conditions (8-10), in addition to its use as replacement therapy for malignant hyperphenylalaninemia (11), a congenital defect of BH4 biosynthesis.
(13) and brain (11, 14) . Ponzone et al. (12) have shown that BH4 administration caused an initial increase in plasma BH4, which was followed by an increase in RBC BH4. Mature RBCs have only trace activity of GTP cyclohydrolase (15) , the rate-limiting enzyme in BH4 biosynthesis (16) , while mature RBCs are rich in the BH4 recycling system, i.e. dihydropteridine reductase (17) . Therefore, it could be hypothesized that the majority of BH4 in peripheral RBCs may be derived from plasma, and that the RBC may play an important role as a source of BH4 in the circulation.
Other studies have demonstrated that plasma and RBC BH4 are increased by a phenylalanine load in healthy human subjects (18) and in a patient with congenital BH4 deficiency along with high level of plasma phenylalanine (12) . Therefore phenylalanine levels are thought to be one of the factors regulating RBC and plasma BH4 levels.
Furthermore, a recent autoradiographic study in rats using radioactive BH4 (13) demonstrated that exogenous BH4 was distributed mainly into liver and kidney, and this distribution changed with development. Developmental changes in RBC BH4 may be an important factor affecting the pharmacological behavior and clinical efficacy of administered BH4. However, little is known about BH4 concentrations in blood, especially RBC BH4 concentrations and the permeability of the RBC membrane to BH4. In this study, the developmental changes in (1) BH4 levels in plasma and RBC, (2) RBC GTP cyclohydrolase activity, (3) RBC membrane permeability to BH4, and (4) plasma phenylalanine levels, both in Wistar rats and healthy human subjects were investigated.
METHODS AND MATERIALS
Human subjects. Human blood samples were collected from inpatients and outpatients at the Osaka Medical College Hospital, Japan. Cord blood (n=36) was collected from a placental vein immediately after the placenta was delivered. Blood from the products of a complicated pregnancy or premature delivery was excluded. Blood samples from neonates (n=62), infants (n=24), and children (n=40) were from the residua of blood samples drawn for other laboratory tests. Each age group was defined as follows: less than 1 month (neonates, mean age; 27.3 days), 1 month to 12 months (infants, mean age; 5.6 months), and over 1 year to 15 years old (children, mean age; 7.1 years). Adult blood was drawn from healthy volunteers aged from 23 to 37 years (mean age; 28.3 years). We excluded subjects who were diagnosed as having malignant diseases, autoimmune diseases, severe allergies, who were being treated with steroids or other immunomodulating agents, or who had symptoms or laboratory evidence of viral/bacterial infections (e.g. recent febrile episodes, diarrhea, or a positive C-reactive protein). Most blood samples were residual samples from negative screening tests for rare metabolic or endocrine disorders. 
RESULTS
Human plasma and RBC BH4 contents Both plasma and RBC BH4 levels were similar across all age groups (Table 1) . Only children's plasma and RBC BH4 were significantly higher than in the neonate and infant groups, as has been reported previously (21) . RBC BH4 levels did not significantly differ from those in plasma (Table 1) . BH4 contents in Wistar rat plasma and RBC BH4 levels in Wistar rat plasma and RBCs were higher than those of human subjects (Table 2 ). There were no significant differences in plasma BH4 concentrations among the rat groups, except that plasma BH4 were significantly greater in 1-week-old rats than in 3-week-old rats. Regarding RBC, the BH4 level in 1-week-old rats was significantly greater than those in 4-, 6-, and 10-week-old rats. The developmental change was more prominent in RBCs than in plasma.
RBC-to-plasma BH4 concentration ratios
The RBC-to-plasma ratio of BH4 in humans did not differ among the various age groups. However, the RBC-to-plasma ratio of BH4 in rats was very high compared with those in humans, and the ratio in rats was also found to be very much greater in the younger age groups (Table 3) .
GTP cyclohydrolase activity in human and rat RBCs
In human RBC, GTP cyclohydrolase activity was slightly, but not significantly (Fig.  1A) . The increasing rate of cellular BH4 was also linearly correlated with the BH4 concentration in the medium (Fig.  1B) . As shown in 
DISCUSSION
These results demonstrate that human RBCs and plasma contain almost the same amounts of BH4 in all age groups (Tables 1, 3 ). This finding may be Table  6 . Plasma phenylalanine concentrations.
* Significantly different from cord , infant and adult by ANOVA using Fisher PLSD (at 99.5%).
consistent with the hypothesis that the RBC may act as a simple container for BH 4 in the circulation.
On the other hand, Wistar rats were demonstrated to be quite different from humans in terms of BH4 cellular disposition, and developmental changes. Rat RBC BH4 levels were considerably higher than that of plasma in all age groups (Tables  2, 3 ). The fact that rat RBCs were richer in GTP cyclohydrolase activity than human RBCs (Table 4 ) may explain the gap between rat RBC and plasma BH4 levels. Regarding the developmental changes, however, there was no correlation between the enzyme activity and RBC BH4 content, especially in the RBCs of 1-week-old rats, which had the highest BH4 content among the age groups, yet had lower GTP cyclohydrolase activity than did the 3-and 4-week-old rats. This indicates that enhanced in situ biosynthesis of BH4 may not be responsible for the higher neonatal Wistar rat RBC BH4 content.
The question arises whether the permeability of the RBC membrane in younger animals is limited by BH4 biosynthesized intracellularly, or whether BH4 influx into the RBC may exceed BH4 efflux, especially in the neonatal Wistar rat. The former assumption is not compatible with the finding that the developmental changes in the permeability coefficient are not observed while the RBC BH4 content changed dramatically. The latter assumption, that BH4 accumulates in the cells by a flux mechanism, was also not consistent with the in vitro experiments which demonstrated that rat RBCs appeared to be more permeable for efflux than influx of BH4 (Table 5) .
Phenylalanine is another factor which may influence RBC and plasma BH4 levels. Previous investigations have demonstrated that plasma BH4 was elevated by a phenylalanine load, both in humans (12, 18) and rats (21) . However, in the present study, plasma phenylalanine levels did not differ among the age groups either in humans or Wistar rats, while the phenylalanine level was slightly higher in human cord blood than other age groups (Table 6 ). Thus, regulation of BH4 biosynthesis by phenylalanine could not explain the higher BH4 levels in neonatal rat RBCs. Vol.41, No.6, Factors other than those examined appear to be responsible for maintaining higher RBC BH4 levels in younger rats. For folate, another pterin in animals, an RBC binding protein has been suggested as an important regulator of uptake into the cells, because the binding capacity of RBCs was increased in folate-deficient rats (22). If a specific BH4-binding protein also exists in plasma or cells, intracellular BH4 levels could be regulated by such a binding protein. In our preliminary studies, the majority of BH4 in human plasma was found in the protein fraction, rather than existing in the unbound form (data not shown). Since only unbound BH4 could penetrate into the cells, the RBC may function as a reservoir for unbound BH4 in the circulation, especially when excess BH4 exists.
In conclusion, the present study demonstrated that the BH4 dynamics in RBC were significantly different among species. In contrast to humans, rats showed remarkable developmental changes in the RBC BH4 content. However, these changes could not be simply explained by developmental changes in either the biosynthesizing activity or the permeability to BH4, or the plasma phenylalanine levels. Other factors which participate in maintaining cellular BH4, such as plasma and RBC BH4-binding may be involved.
